US 8,637,307 B2 · Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool

Abstract

Provided are a system and methods for selectively inducing expansion of a population of T cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of CTLs, preferably human CTLs. In addition, T cell proliferation can be induced without the need for antigen, thus providing an expanded T cell population that is polyclonal with respect to antigen reactivity. Further provided are methods for using the system and methods to screen and identify antigens related to specific diseases or conditions, tumors, autoimmune disorders, or an infectious disease or pathogen, and to identify target molecule for research purposes, or for developing a vaccine based thereon.

Claims4

Dependent claims

An isolated population of T cells expanded and restimulated by a method comprising:

contacting a population of T cells with an engineered K562 cell, said engineered K562 cell comprising on its surface:
1) an exogenous antibody that binds to CD3 or CD2, 2) a molecule that binds CD28, wherein the molecule that binds CD28 is selected from the group consisting of anti-CD28 antibody, CD80, and CD86, and 3) the natural 4-1BBL;
and expanding said population of T cells by culturing said population of T cells under conditions and time sufficient to induce cell division, wherein said contacting and/or said culturing occurs in the absence of exogenously added cytokines, wherein said T cells so expanded are substantially free of said engineered K562 cell, followed by restimulating said T cells wherein said T cells remain in exponential growth after restimulation.

Dependencies are inferred from the claim text.

Facts

Application

12/777,053Filed 10 May 2010 · division

Priority

3 Jan 2002

Published

US 2010/0261269 A114 Oct 2010

Granted

28 Jan 2014

Term ends

Not estimatedThe source records don’t support an estimate.

Classification21 codes

C12N 5/0634
Vertebrate cells: cells from the blood or the immune system
A61K 35/17
Blood; Artificial blood: lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 40/19
Characterised by the cell type used: dendritic cells
A61K 40/24
Characterised by the effect or the function of the cells: antigen-presenting cells [APC]

Family

Application60/346,092Us provisional application · filed 3 Jan 2002

Application10/336,135Parent of this continuation-in-part · filed 3 Jan 2003

Application10/336,224Parent of this continuation-in-part · filed 3 Jan 2003

Application10/461,283Parent of this division · filed 13 Jun 2003

US 2010/0261269 A1Pre-grant publication · published 14 Oct 2010

US 7,745,140 B2Parent of this division

US 7,670,781 B2Parent of this continuation-in-part

Application10/461,283Parent of this continuation-in-part

US 7,638,325 B2Parent of this continuation-in-part

US 2003/0147869 A1Published application

US 2003/0224520 A1Published application

US 2004/0101519 A1Published application

US 8,637,307 B2This patent

From the US filing history. Foreign family members aren’t listed.

Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool

Life of this patent

Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool

Life of this patent

Abstract

Claims4